<DOC>
	<DOC>NCT00322374</DOC>
	<brief_summary>Tumor response information was obtained for all participants who received at least 2 cycles of study drug, underwent requisite baseline and on-treatment disease assessments and had at least one post-treatment assessment. Tumor response assessment in evaluable participants was done according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.</brief_summary>
	<brief_title>Phase I Combination w/ Epirubicin</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Women ≥18 years Histologically or cytologically confirmed diagnosis of metastatic breast cancer Measurable or nonmeasurable disease defined by Response Evaluation Criteria In Solid Tumors (RECIST) Number of prior chemotherapy lines of treatment in the metastatic setting ≥2</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>